Semaglutide can yield weight loss, lower heart issues for at least four years in non-diabetic adults with overweight

Credit: Unsplash/CC0 Public Domain Two studies are being presented at this year’s European Congress on Obesity (ECO) in Venice, Italy (12-15 May), based on the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial from the same international author group. The first new study, led by Professor Donna Ryan from Pennington Biomedical Research Center, New Orleans, U.S.,…

Read More

Hypofractionated RT Limits Toxic Effects in Cervical Cancer

TOPLINE: A hypofractionated intensity-modulated radiotherapy (IMRT) may be safe and well-tolerated in women with cervical cancer undergoing pelvic irradiation with concurrent chemotherapy following surgical resection, results from the phase 2 POHIM-CCRT trial suggested. METHODOLOGY: To date, no studies have assessed the treatment outcomes and toxic effects of hypofractionated IMRT following radical hysterectomy in patients with…

Read More

Do Antipsychotic Overprescribing Warning Letters Work?

Warning letters to primary care physicians (PCPs) regarding overprescription of quetiapine were helpful in reducing overprescribing of this agent, new research suggested. Investigators analyzed data from an earlier trial that compared prescribing patterns in 5055 PCPs who receive a placebo letter or three warning letters informing them that their prescribing of quetiapine was high and…

Read More

DOJ Launches Task Force on Healthcare Monopolies: Will It Make A Difference?

The U.S. Department of Justice (DOJ) announced last week that it is launching the Antitrust Division’s Task Force on Health Care Monopolies and Collusion (HCMC). What effect will this have on the healthcare industry? Experts have varying opinions. The HCMC will include civil and criminal prosecutors, economists, healthcare experts, technologists, data scientists, investigators and policy…

Read More
error: Content is protected !!